| Garcia2009 - Long-term Clinical Symptoms Post-Dengue | 2009 | Int J Infect Dis | 133 / 110 | Post-dengue syndrome, FcγRIIa polymorphism, autoimmunity, Cuba DENV-4 |
| Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism | 2010 | Am J Trop Med Hyg | 23 / 83 | FcγRIIa-RR protective against symptomatic dengue; asymptomatic infection; Cuba population genetics |
| Tan1997 - ANA Range in Healthy Individuals | 1997 | Arthritis & Rheumatism | 381 / 267 | ANA normal range; healthy-population reference; 15-lab multicentre; 1:40–1:320 |
| Satoh2012 - ANA Prevalence in United States | 2012 | Arthritis & Rheumatism | 424 / 386 | ANA prevalence US population; NHANES; sociodemographic correlates; 13.8% at 1:80 |
| Li2019 - ANA Epidemiology in Chinese Healthy Population | 2019 | J Clin Lab Anal | 39 / 37 | ANA prevalence Chinese health-checkup population; AMA-M2; anti-SSA; 14.01% at >1:100 |
| Aringer2019 - 2019 EULAR ACR SLE Classification Criteria | 2019 | Arthritis & Rheumatology | 2248 / 1973 | 2019 EULAR/ACR SLE criteria; ANA ≥1:80 as mandatory entry criterion; sensitivity 96.1% |
| Dinse2022 - Increasing ANA Prevalence in United States | 2022 | Arthritis & Rheumatology | 53 / 68 | Rising ANA prevalence in US 1988–2012; 11.0%→16.1%; adolescent increase; NHANES |
| Berlin2007 - Autoantibodies in Nonautoimmune Individuals during Infections | 2007 | Ann NY Acad Sci | 78 / 60 | ANA 21.7% during acute viral infections vs. 3.8% controls; anti-annexin-V/prothrombin; multi-infection comparison |
| Johnson2022 - Infectious Diseases Autoantibodies and Autoimmunity | 2022 | J Autoimmun | 52 / 52 | Molecular mimicry, bystander activation, epitope spreading; review of infection-triggered autoimmunity mechanisms |
| Sungnak2025 - Distinct Immune Responses Asymptomatic Symptomatic Dengue | 2025 | Sci Transl Med | 1 / 1 | scRNA-seq + V(D)J sequencing; asymptomatic vs. DF vs. DHF; CD8 TEM effector vs. exhausted; NK FcεRIγ phenotype; ADE transcriptomics; IGHG1/IGHA1 plasmablasts; public BCR clonotype; IL-10; IFN-α; Thailand DENFREE cohort |
| Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection | 2006 | Viral Immunology | 182 / 110 | NS1 molecular mimicry; anti-platelet IgM autoAbs; endothelial apoptosis; NF-κB inflammation; DHF/DSS; NCKU Taiwan |
| Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis | 2011 | Exp Biol Med | 128 / 107 | NS1 molecular targets (PDI/vimentin/HSP60/ATP-synthase β); C-terminal NS1 aa 311–352; WGNGCG coagulation motif; anti-prM/HSP60; flavivirus comparison; acute-phase autoimmunity |
| Guzman2016 - Dengue Infection | 2016 | Nat Rev Dis Primers | 687 / 634 | Comprehensive dengue review; global burden; virology; ADE conditional virulence; pathophysiology (NS1-TLR4, thrombin, APTT, thrombocytopenia, complement, liver); host genetics Table 2; vaccines (CYD-TDV, TAK-003, TV003, subunit, inactivated); vector biology; vector control (Cuba, Singapore, Wolbachia, SIT) |
| Bruhns2009 - FcγR Specificity and Affinity for IgG Subclasses | 2009 | Blood | 1444 / 1303 | SPR affinity of all 6 hFcγRs for IgG1–4; H131 4.5× higher IgG2 affinity than R131; FcγRIIB ~43× weaker than FcγRIIA for IgG1; FcγRIIIA-V158 monomeric IgG3 binding; fucosylation effect on FcγRIII |
| Li2018 - Increased Risk of Autoimmune Diseases in Dengue | 2018 | J Infect | 38 / 40 | ICD-coded NHIRD cohort (n=12,506); aHR 1.88 overall; primary adrenocortical insufficiency most frequent [aHR 2.05]; ADEM [aHR 3.80]; SLE [aHR 3.50]; GBS non-significant; TLR/adrenocortical mechanism; critiqued by Shih2023 |
| Shih2023 - Autoimmune Disease Risk After Dengue | 2023 | PLoS Negl Trop Dis | 17 / 18 | Population-based cohort (63,814 lab-confirmed dengue); Taiwan NHIRD; only ADEM elevated after dengue (aHR 2.72); refutes Li et al. 2018 broad autoimmune claim; 51.4% misclassification rate in prior studies; NS1 RDT rollout impact |
| Wan2012 - Autoimmunity in Dengue Pathogenesis | 2012 | J Formos Med Assoc | 92 / 77 | Capstone NCKU review; autoantibody kinetics (acute peak, months persistence); LYRIC/RGD/capsid mimicry; intrinsic ADE; NS1 vaccine paradox; Taiwan epidemiology |
| Chatterjee2024 - ANA Detection in Dengue Kolkata | 2024 | Virulence | 2 / 2 | ANA in acute dengue; HEp-2 IIFA 54.8% vs. 10.3% controls; LIA 18.5%; ~66% IIFA-positives non-specific; MCTD and myositis significantly elevated; Kolkata India hospital-based; n=135 |
| Seet2007 - Post-Infectious Fatigue Syndrome in Dengue | 2007 | J Clin Virology | 140 / 126 | Post-dengue fatigue; 24.4% at 2 months; severity-independence; OR 9.687 female sex; Singapore DEN-1 outbreak; n=127 |
| Bos2025 - Longitudinal Antibody Dynamics After Dengue | 2025 | medRxiv (PREPRINT) | 0 / 0 | XR E-IgG rising 6–18M post-primary (t½=−2.13y); NS1-IgG waning (t½≈2.1y); EDI/II vs EDIII domain specificity; IgA/IgM/IgG3/IgG4 kinetics at 18M; Nicaragua HIMJR pediatric cohort; n=79 |
| Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients | 2001 | J Med Virol | 195 / 95 | Foundational IgM anti-platelet autoantibody study; DENV-3 Taiwan 1998–99; lysis severity-correlated, aggregation inhibition not; primary-infection context; dengue-specific vs. JEV/HCV/EV71 |
| Morel2014 - Autoimmune Response in Children With Dengue | 2014 | Reumatol Clin | null / 0 | MAS/secondary HLH in 3 pediatric dengue cases; ANA/anti-dsDNA negative in all cases; anticardiolipin IgM positive in mild Case 1 only; MAS responded to methylprednisolone; Paraguay endemic setting |
| Palacios2016 - Autoimmunity in Dengue Literature Review | 2016 | Reumatol Clin | 1 / 0 | Letter to editor; responds to Morel2014; adds MAS+nephrotic syndrome, SLE+ANA+/anti-dsDNA+ (Talib 2013), retinal vasculitis; cites Wan2012 autoantibody-severity correlation; calls for larger endemic studies |
| Oishi2003 - PAIgG and Thrombocytopenia in Secondary Dengue | 2003 | J Med Virol | 62 / 41 | PAIgG–thrombocytopenia inverse correlation in secondary dengue; anti-dengue IgG (not anti-platelet autoAb) in platelet eluates; FcγRII not required for dengue-platelet binding; Philippines; n=53 |
| Saito2004 - PAIgG and PAIgM in Secondary Dengue | 2004 | Clin Exp Immunol | 138 / 89 | PAIgG + PAIgM in secondary dengue; both inversely correlated with platelet count; anti-dengue IgM confirmed in platelet eluates; PAIgM DHF predictor (specificity 92.1%, cut-off >20 ng/10⁷); FcγR bypass for PAIgM; Philippines; n=78 |
| Vo2020 - Autoantibody Profiling in Dengue | 2020 | Pathogens | 10 / 12 | 123-antigen protein microarray; 80 IgM + 6 IgG autoantibodies elevated vs. HD; primary > secondary IgG autoantibody inversion; no ASD vs. DF/DHF difference in total load; 19 IgG autoantibodies (complement, coagulation, nuclear antigens) positively correlated with platelet count in DHF; Cambodia pediatric cohort; n=40 |
| Dejnirattisai2010 - Anti-prM Antibodies Enhance Dengue ADE | 2010 | Science | 891 / 820 | Anti-prM dominant structural antibody (~60%); full cross-reactivity DENV-1–4; neutralisation ceiling 10–60% from incomplete prM cleavage; 10^5-fold monocyte/DC ADE; FcγR-dependent; all current vaccines use native prM; dengue-specific vs. JEV; Thailand n=7 donors, 3020 B cell lines; erratum July 2010 |
| Bhatt2020 - Dengue Pathogenesis Review | 2021 | Curr Microbiol | 300 / 294 | Narrative review: sfRNA→TRIM25→RIG-I IFN suppression; sfRNA→Dicer siRNA inhibition; Katzelnick 2017 ADE window 1:21–1:80 (n=6684 Nicaragua); OAS low-avidity CD8+ cytolytic loss; NS1 replication complex cofactor; glycocalyx: heparanase + cathepsin L; MIF-autophagy viral amplification; Th1→Th2 + Treg IL-10; DENV-1 higher NS1/primary viremia; Asian DENV-2 NS3 salivary gland replication; India Manipal |
| Zhou2007 - Polyreactive Antibodies Natural Antibody Function | 2007 | J Autoimmun | 194 / 176 | Polyreactive antibodies: germline IgM binding multiple unrelated self/non-self antigens; half-life ~8h; PAB cells 15–20% adult peripheral blood; antibacterial function; distinction from pathogenic autoantibodies; interpretive framework for non-specific dengue ANA |
| Gawali2021 - ANA Prevalence in Seroconverted Dengue Patients | 2021 | Int J Appl Res | null / null | ANA in dengue IgG-seroconverted patients at 6 months; 18.33% HEp-2 IIFA positive; AC-1 dominant (81.81%); no control group; Gwalior Madhya Pradesh India; n=120 |
| Velazqueza2017 - SLE vs Dengue Case Series | 2017 | Rev Colomb Reumatol | 1 / 1 | SLE + dengue in 2 pediatric patients; ANA 1:1280 + antinucleosome + anti-dsDNA in both; Case 2 SLE diagnosed 2 months post-dengue; Guadalajara Jalisco Mexico; molecular mimicry, FcR polymorphism; n=2 case series |
| Pang2017 - DHF Pathogenesis Review | 2017 | Virologica Sinica | 74 / 67 | Narrative review; DHF pathogenesis: NS1-complement-C5b-C9-NLRP3; anti-NS1 GPI-signalling→viral replication; IL-10→T cell apoptosis→impaired clearance; sfRNA IFN suppression; ADE anti-E/prM; OAS T cells; Tsinghua University China |
| Rajadhyaksha2012 - Dengue Evolving into SLE and Lupus Nephritis | 2012 | Lupus | 54 / 35 | Primary DENV-1 → SLE + Class IV lupus nephritis in 4 weeks; ANA 1:320 + anti-dsDNA + anti-cardiolipin IgM+IgG+; biopsy-confirmed; Mumbai India; n=1 case report |
| Jardim2012 - Autoimmune Features DHF Case Report | 2012 | Braz J Infect Dis | 6 / 12 | Secondary DENV-3 DHF; ANA 1/320 mitotic spindle pattern; cryoglobulinemia; selective C3 depression (C4 normal); LE cells in pleural fluid; DIC; all resolved at follow-up; anti-dsDNA negative; Campinas Brazil; n=1 case report |
| Codes2002 - Autoantibodies in Acute Viral Hepatitis | 2002 | Rev Soc Bras Med Trop | null / null | ANA 20.5% acute → 6.4% convalescent in viral hepatitis (IIF ≥1:40); ASMA 14.8% → 3.9%; n=156 prospective; no severity/chronification association; not a dengue paper — viral-infection ANA transience comparator baseline; Salvador Brazil |
| Chaturvedi2001 - Cytotoxic Factor Autoantibodies DHF | 2001 | FEMS Immunol Med Microbiol | null / 1 | Anti-hCF autoantibodies inversely correlated with DHF severity (96% DF → 8% DHF-IV); reverse correlation with hCF titres; hCF = dengue-specific CD4 T cell cytokine (Chaturvedi group concept, unvalidated externally); 1997 WHO DHF grades I–IV; 1996 North India epidemic; n=136 |
| Cheng2015 - NS1 P311-330 Anti-PDI Autoantibodies in DHF | 2015 | Am J Trop Med Hyg | 22 / 19 | NS1 P311–330 PDI-specific cross-reactive epitope; anti-PDI/HSP60/vimentin elevated in DHF; anti-PDI IgG vs. anti-P311–330 IgG r=0.732; HSP60 uses distinct NS1 epitope; infection-order independence; NCKU Tainan lab; Vietnamese DHF/DF paediatric cohort; n=15 DHF + 2 DF |
| Santosa2012 - Delayed SLE Diagnosis Dengue Serology | 2012 | Scand J Rheumatol | 16 / 11 | False-positive dengue IgM in SLE (polyclonal low-affinity IgM); RF-positive 15% false-positive with Panbio kit; ANA-positive 0/10; delayed SLE diagnosis case report; NS1 antigen and RT-PCR preferred in autoantibody-positive patients; diagnostic algorithm; Singapore NUHS/SGH |
| Farias2024 - Dengue Mimickers | 2024 | Rev Soc Bras Med Trop | 13 / 11 | Clinical differential diagnosis of dengue across infectious/rheumatological/haematological/neurological categories; SLE-dengue bidirectional confusion; CHIKV ~6% serology cross-reactivity; GBWT >3mm as DHF marker; dengue-triggered KD/ITP/necrotizing myopathy/sacroiliitis; DENV-YFV co-infection exclusion; Brazil 2024 epidemic >6M cases; narrative review — secondary source |
| Hung2008 - Anti-Platelet Anti-Endothelial Autoantibodies Vietnam | 2008 | Am J Infect Dis | 3 / 1 | Anti-platelet IgM elevated in infants (primary) and children (secondary); anti-EC isotype shift: IgM-only in infants vs. IgM+IgG in children; thrombomodulin elevated in both groups (in vivo endothelial damage marker); no autoantibody-severity correlation; HCMC Vietnam 1998–2002; n=50 infants + 37 children |
| Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review | 2024 | Arch Microbiol | 7 / 8 | Narrative review of autoantibody-mediated dengue pathogenesis; profibrinolysis/hyperfibrinolysis dual mechanism via anti-plasminogen; anti-DSG pemphigus/acantholysis (new mechanism type); anti-NS1 AECA + hepatic murine model; coagulation factor homology across ≥12 DENV regions; Kolkata India — no original patient data |
| Pearce2016 - Analysis of Matched Case-Control Studies | 2016 | BMJ | 684 / 575 | Matched case-control study methodology; matching does not eliminate confounding; unconditional vs. conditional analysis; standard analysis may be preferable to matched analysis; sparse strata rule; not a dengue paper — epidemiological methods reference for age-matched case-control designs |
| Iwagami2022 - Introduction to Matching in Case-Control and Cohort Studies | 2022 | Ann Clin Epidemiol | 115 / 122 | Matching tutorial: case-control vs. cohort matching; matching ratios; over-matching; propensity score matching; risk set sampling; unconditional analysis “not recommended” (contradicts Pearce2016); not a dengue paper — epidemiological methods reference |
| Hertanti2024 - Fatigue and Post-Infectious Fatigue in Dengue | 2024 | eClinicalMedicine | 7 / 9 | Fatigue/PIF meta-analysis (40 studies, 38,406 patients); acute fatigue 59% [PI 0.03–1.00], PIF 20% [PI 0.02–0.77] under I²≈99%; PIF risk factors female sex 1.65 / DHF 1.80 / comorbidities 2.14; measures no ANA; recalibrates Seet2007 female OR 9.687→pooled 1.65; first ingest into ANA↔fatigue thread |